Although the safety and efficacy of hepatitis C therapies have been studied extensively in patients between the ages of 18 and 65, patients who are older than 65 still remain an understudied and difficult-to-treat population. Clinical Gastroenterology and Hepatology
Clinicians should be aware that LVADs may have this effect and make every effort to confirm the absence of hepatitis C infection "in order to prevent undue alarm among patients and to prevent candidates from being denied transplantation," according to researchers. Heartwire
William Balistreri, MD, reviews the current state of the field in regard to the prevalence, screening, diagnosis, pathophysiology, and treatment of NAFLD, as framed by data presented at AASLD 2008. Medscape Gastroenterology
